Discovery of Highly Potent and Selective Small Molecule ADAMTS-5 Inhibitors That Inhibit Human Cartilage Degradation via Encoded Library Technology (ELT)
-
- Hongfeng Deng
- ELT Boston, Platform Technology and Science, GlaxoSmithKline, Waltham, Massachusetts, United States
-
- Heather O’Keefe
- ELT Boston, Platform Technology and Science, GlaxoSmithKline, Waltham, Massachusetts, United States
-
- Christopher P. Davie
- ELT Boston, Platform Technology and Science, GlaxoSmithKline, Waltham, Massachusetts, United States
-
- Kenneth E. Lind
- ELT Boston, Platform Technology and Science, GlaxoSmithKline, Waltham, Massachusetts, United States
-
- Raksha A. Acharya
- ELT Boston, Platform Technology and Science, GlaxoSmithKline, Waltham, Massachusetts, United States
-
- G. Joseph Franklin
- ELT Boston, Platform Technology and Science, GlaxoSmithKline, Waltham, Massachusetts, United States
-
- Jonathan Larkin
- Biopharm Discovery, Medicines Discovery and Development, GlaxoSmithKline, Upper Merion, Pennsylvania, United States
-
- Rosalie Matico
- Biological Reagent and Assay Development, Platform Technology and Science, GlaxoSmithKline, Upper Providence, Pennsylvania, United States
-
- Michael Neeb
- Center of Excellence for External Drug Discovery, Medicines Discovery and Development, GlaxoSmithKline, Upper Merion, Pennsylvania, United States
-
- Monique M. Thompson
- Biological Reagent and Assay Development, Platform Technology and Science, GlaxoSmithKline, Upper Providence, Pennsylvania, United States
-
- Thomas Lohr
- Biopharm Discovery, Medicines Discovery and Development, GlaxoSmithKline, Upper Merion, Pennsylvania, United States
-
- Jeffrey W. Gross
- Screening and Compound Profiling, Platform Technology and Science, GlaxoSmithKline, Upper Providence, Pennsylvania, United States
-
- Paolo A. Centrella
- ELT Boston, Platform Technology and Science, GlaxoSmithKline, Waltham, Massachusetts, United States
-
- Gary K. O’Donovan
- ELT Boston, Platform Technology and Science, GlaxoSmithKline, Waltham, Massachusetts, United States
-
- Katie L. (Sargent) Bedard
- ELT Boston, Platform Technology and Science, GlaxoSmithKline, Waltham, Massachusetts, United States
-
- Kurt van Vloten
- ELT Boston, Platform Technology and Science, GlaxoSmithKline, Waltham, Massachusetts, United States
-
- Sibongile Mataruse
- ELT Boston, Platform Technology and Science, GlaxoSmithKline, Waltham, Massachusetts, United States
-
- Steven R. Skinner
- ELT Boston, Platform Technology and Science, GlaxoSmithKline, Waltham, Massachusetts, United States
-
- Svetlana L. Belyanskaya
- ELT Boston, Platform Technology and Science, GlaxoSmithKline, Waltham, Massachusetts, United States
-
- Tiffany Y. Carpenter
- Muscle Metabolism Discovery Performance Unit, Medicines Discovery and Development, GlaxoSmithKline, Research Triangle Park, North Carolina, United States
-
- Todd W. Shearer
- Muscle Metabolism Discovery Performance Unit, Medicines Discovery and Development, GlaxoSmithKline, Research Triangle Park, North Carolina, United States
-
- Matthew A. Clark
- ELT Boston, Platform Technology and Science, GlaxoSmithKline, Waltham, Massachusetts, United States
-
- John W. Cuozzo
- ELT Boston, Platform Technology and Science, GlaxoSmithKline, Waltham, Massachusetts, United States
-
- Christopher C. Arico-Muendel
- ELT Boston, Platform Technology and Science, GlaxoSmithKline, Waltham, Massachusetts, United States
-
- Barry A. Morgan
- ELT Boston, Platform Technology and Science, GlaxoSmithKline, Waltham, Massachusetts, United States
収録刊行物
-
- Journal of Medicinal Chemistry
-
Journal of Medicinal Chemistry 55 (16), 7061-7079, 2012-08-14
American Chemical Society (ACS)